Laboratory Corp. of America Stake (LH) Trended Somewhat Positive News Coverage, Research Finds

Laboratory Corp. of America Stake (LH) Trended Somewhat Positive News Coverage, Research Finds

Headlines about Laboratory Corp. of America Holdings (NYSE:LH) have been trending somewhat positive recently, Alpha One Sentiment Analysis reports. Alpha One, a unit of Accern, identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Laboratory Corp. of America Holdings earned a media sentiment score of 0.23 on Alpha One’s scale. Alpha One also gave news articles about the medical research company an impact score of 83 out of 100, meaning that recent media coverage is very likely to have an impact on the stock’s share price in the immediate future.

Here are some of the media stories that may have effected Alpha One Sentiment’s analysis:

Shares of Laboratory Corp. of America Holdings (NYSE:LH) traded down 0.34% during midday trading on Friday, hitting $141.58. 611,264 shares of the stock were exchanged. The firm has a 50 day moving average of $140.83 and a 200-day moving average of $136.42. The stock has a market cap of $14.48 billion, a P/E ratio of 19.45 and a beta of 0.94. Laboratory Corp. of America Holdings has a 12 month low of $119.51 and a 12 month high of $146.63.

Laboratory Corp. of America Holdings (NYSE:LH) last announced its earnings results on Tuesday, April 25th. The medical research company reported $2.22 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.19 by $0.03. Laboratory Corp. of America Holdings had a net margin of 6.85% and a return on equity of 16.97%. The business had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the firm posted $2.02 earnings per share. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. Equities research analysts anticipate that Laboratory Corp. of America Holdings will post $9.44 EPS for the current year.

LH has been the topic of a number of analyst reports. Robert W. Baird cut shares of Laboratory Corp. of America Holdings from an “outperform” rating to a “neutral” rating and set a $138.00 target price on the stock. in a research report on Monday, February 6th. Barclays PLC raised their price target on shares of Laboratory Corp. of America Holdings from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Tuesday, March 7th. Zacks Investment Research raised shares of Laboratory Corp. of America Holdings from a “sell” rating to a “hold” rating in a report on Wednesday, February 8th. Canaccord Genuity raised their price target on shares of Laboratory Corp. of America Holdings from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 17th. Finally, Mizuho raised their price target on shares of Laboratory Corp. of America Holdings from $135.00 to $139.00 and gave the stock a “neutral” rating in a report on Friday, February 17th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the stock. Laboratory Corp. of America Holdings presently has an average rating of “Buy” and an average target price of $155.75.

In other news, Director Jean-Luc Belingard sold 992 shares of the company’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $142.19, for a total value of $141,052.48. Following the transaction, the director now directly owns 32,935 shares in the company, valued at $4,683,027.65. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Lance Berberian sold 3,613 shares of the company’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $139.84, for a total transaction of $505,241.92. Following the completion of the transaction, the senior vice president now owns 5,789 shares in the company, valued at $809,533.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,905 shares of company stock worth $973,975. Company insiders own 1.14% of the company’s stock.

Laboratory Corp. of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LH”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment